[1]
|
Jang, J.H., Seo, J.Y., Bang, S.H., et al. (2010) Establishment of Reference Intervals for von Willebrand Factor Antigen and Eight Coagulation Factors in a Korean Population Following the Clinical and Laboratory Standards Institute Guidelines. Blood Coagulation & Fibrinolysis, 21, 251-255. https://doi.org/10.1097/MBC.0b013e3283367931
|
[2]
|
Belvini, D., Salviato, R., Radossi, P., et al. (2005) Molecular Genotyping of the Italian Cohort of Patients with Hemophilia B. Haematologica, 90, 635-642.
|
[3]
|
Lane, S. (1840) Haemorrhagic Diathesis. Successful Transfusion of Blood. The Lancet, 35, 185-188.
https://doi.org/10.1016/S0140-6736(00)40031-0
|
[4]
|
Ingram, G.I. (1997) The History of Haemophilia. Haemophilia, 3, 5-15.
https://doi.org/10.1111/j.1365-2516.1997.tb00168.x
|
[5]
|
Ljung, R., Kenet, G., Mancuso, M.E., et al. (2016) BAY 81-8973 Safety and Efficacy for Prophylaxis and Treatment of Bleeds in Previously Treated Children with Severe Haemophilia A: Results of the LEOPOLD Kids Trial. Haemophilia, 22, 354-360. https://doi.org/10.1111/hae.12866
|
[6]
|
Santagostino, E., Negrier, C., Klamroth, R., et al. (2012) Safety and Pharmacokinetics of a Novel Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Hemophilia B Patients. Blood, 120, 2405-2411.
https://doi.org/10.1182/blood-2012-05-429688
|
[7]
|
Negrier, C., Knobe, K., Tiede, A., et al. (2011) Enhanced Pharmacokinetic Properties of a Glyco-PEGylated Recombinant Factor IX: A First Human Dose Trial in Patients with Hemophilia B. Blood, 118, 2695-2701.
https://doi.org/10.1182/blood-2011-02-335596
|
[8]
|
Soucie, J.M., Monahan, P.E., Kulkarni, R., et al. (2018) The Frequency of Joint Hemorrhages and Procedures in Nonsevere Hemophilia A vs B. Blood Advances, 2, 2136-2144. https://doi.org/10.1182/bloodadvances.2018020552
|
[9]
|
Valentino, L.A., Hakobyan, N. and Enockson, C. (2008) Blood-Induced Joint Disease: The Confluence of Dysregulated Oncogenes, Inflammatory Signals, and Angiogenic Cues. Seminars in Hematology, 45, S50-S57.
https://doi.org/10.1053/j.seminhematol.2008.03.017
|
[10]
|
Peters, R.T., Toby, G., Lu, Q., et al. (2013) Biochemical and Functional Characterization of a Recombinant Monomeric Factor VIII-Fc Fusion Protein. Journal of Thrombosis and Haemostasis, 11, 132-141.
https://doi.org/10.1111/jth.12076
|
[11]
|
Wynn, T.T., Gumuscu, B., et al. (2016) Potential Role of a New PEGylated Recombinant Factor VIII for Hemophilia A. Journal of Blood Medicine, 7, 121-128. https://doi.org/10.2147/JBM.S82457
|
[12]
|
Zetterberg, E., Palmblad, J., Wallensten, R., et al. (2014) Angiogenesis Is Increased in Advanced Haemophilic Joint Disease and Characterised by Normal Pericyte Coverage. European Journal of Haematology, 92, 256-262.
https://doi.org/10.1111/ejh.12227
|
[13]
|
Chhabra, E.S., Liu, T.Y., Kulman, J., et al. (2020) BIVV001, a New Class of Factor VIII Replacement for Hemophilia A That Is Independent of von Willebrand Factor in Primates and Mice. Blood, 135, 1484-1496.
https://doi.org/10.1182/blood.2019001292
|
[14]
|
Konkle, B.A., Shapiro, A.D., Quon, D.V., et al. (2020) BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. The New England Journal of Medicine, 383, 1018-1027. https://doi.org/10.1056/NEJMoa2002699
|
[15]
|
Yee, A., Gildersleeve, R.D., Gu, S., et al. (2014) A von Willebrand Factor Fragment Containing the D’D3 Domains Is Sufficient to Stabilize Coagulation Factor VIII in Mice. Blood, 124, 445-452.
https://doi.org/10.1182/blood-2013-11-540534
|
[16]
|
Gringeri, A., Mantovani, L.G., Scalone, L. and Mannucci, P.M. (2003) Cost of Care and Quality of Life for Patients with Hemophilia Complicated by Inhibitors: The COCIS Study. Blood, 102, 2358-2363.
https://doi.org/10.1182/blood-2003-03-0941
|
[17]
|
Kitazawa, T., Igawa, T., Sampei, Z., et al. (2012) A Bis-Pecific Antibody to Factors IXa and X Restores Factor VIII Hemostatic Activity in a Hemophilia A Model. Nature Medicine, 18, 1570-1574. https://doi.org/10.1038/nm.2942
|
[18]
|
Lenting, P.J., Denis, C.V. and Christophe, O.D. (2017) Emicizumab, a Bispecific Antibody Recognizing Coagulation Factors IX and X: How Does It Compare to Factor VIII? Blood, 130, 2463-2468.
https://doi.org/10.1182/blood-2017-08-801662
|
[19]
|
Uchida, N., Sambe, T., Yoneyama, K., et al. (2016) A First-in-Human Phase 1 Study of ACE910, a Novel Factor VIII- Mimetic Bispecific Antibody, in Healthy Subjects. Blood, 127, 1633-1641.
https://doi.org/10.1182/blood-2015-06-650226
|
[20]
|
Ragni, M.V. (2015) Targeting Antithrombin to Treat Hemophilia. The New England Journal of Medicine, 373, 389-391.
https://doi.org/10.1056/NEJMcibr1505657
|
[21]
|
Muczynski, V., Christophe, O.D., Denis, C.V. and Lenting, P.J. (2017) Emerging Therapeutic Strategies in the Treatment of Hemophilia A. Seminars in Thrombosis and Hemostasis, 43, 581-590. https://doi.org/10.1055/s-0037-1604053
|
[22]
|
Bolliger, D., Szlam, F., Suzuki, N., et al. (2010) Heterozygous Antithrombin Deficiency Improves in Vivo Hemostasis in Factor VIII-Deficient Mice. Thrombosis and Haemostasis, 103, 1233-1238. https://doi.org/10.1160/TH09-10-0732
|
[23]
|
Figueiredo, M. (2020, March 18) Novo Nordisk Pauses 3 Clinical Trials of Concizumab amid Safety Concerns. Hemophilia News Today.
https://hemophilianewstoday.com/2020/08/14/novo-nordisk-resumes-phase-3-trials-of-concizumab-in-hemophilia-a-and-b
|
[24]
|
Ray, F. (2020, August 14) Novo Nordisk Resumes Phase 3 Trials of Concizumab in Hemophilia A and B. Hemophilia News Today.
https://hemophilianewstoday.com/2020/08/14/novo-nordisk-resumes-phase-3-trials-of-concizumab-in-hemophilia-a-and-b
|
[25]
|
Broze, G.J., Warren, L.A., Novotny, W.F., et al. (1988) The Lipoprotein-Associated Coagulation Inhibitor That Inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight into Its Possible Mechanism of Action. Blood, 71, 335-343. https://doi.org/10.1182/blood.V71.2.335.335
|
[26]
|
Pasi, K.J., Rangarajan, S., Georgiev, P., et al. (2017) Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. The New England Journal of Medicine, 377, 819-828. https://doi.org/10.1056/NEJMoa1616569
|
[27]
|
Agersø, H., Overgaard, R.V., Petersen, M.B., et al. (2014) Pharmacokinetics of an Anti-TFPI Monoclonal Antibody (Concizumab) Blocking the TFPI Interaction with the Active Site of FXa in Cynomolgus Monkeys after IV and SC Administration. European Journal of Pharmaceutical Sciences, 56, 65-69. https://doi.org/10.1016/j.ejps.2014.02.009
|
[28]
|
Eichler, H., Angchaisuksiri, P., Kavakli, K., et al. (2018) A Randomized Trial of Safety, Pharmacokinetics and Pharmacodynamics of Concizumab in People with Hemophilia A. Journal of Thrombosis and Haemostasis, 16, 2184-2195.
https://doi.org/10.1111/jth.14272
|
[29]
|
Shapiro, A.D., Angchaisuksiri, P., Astermark, J., et al. (2019) Subcutaneous Concizumab Prophylaxis in Hemophilia A and Hemophilia A/B with Inhibitors: Phase 2 Trial Results. Journals Blood, 134, 1973-1982.
https://doi.org/10.1182/blood.2019001542
|
[30]
|
Chowdary, P., Lethagen, S., Friedrich, U., et al. (2015) Safety and Pharmacokinetics of Anti-TFPI Antibody (Concizumab) in Healthy Volunteers and Patients with Hemophilia: A Randomized First Human Dose Trial. Journal of Thrombosis and Haemostasis, 13, 743-754. https://doi.org/10.1111/jth.12864
|
[31]
|
Skinner, M.W., Nugent, D., Wilton, P., et al. (2020) Achieving the Unimaginable: Health Equity in Haemophilia. Haemophilia, 26, 17-24. https://doi.org/10.1111/hae.13862
|
[32]
|
Iorio, A., Skinner, M.W., Clearfield, E., et al. (2018) Core Outcome Set for Gene Therapy in Haemophilia: Results of the coreHEM Multistakeholder Project. Haemophilia, 24, e167-e172. https://doi.org/10.1111/hae.13504
|
[33]
|
Sidonio, R.F., Pipe, S.W., Callaghan, M.U., et al. (2020) Discussing Investigational AAV Gene Therapy with Hemophilia Patients: A Guide. Blood Reviews, 2020, Article ID: 100759. https://doi.org/10.1016/j.blre.2020.100759
|